Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
Primary Objective:
- Assess change in neuronal architecture following long term treatment with dupilumab in
skin biopsies from atopic dermatitis (AD) participants with chronic pruritus
Secondary Objectives:
- Assess change in neuronal architecture following short term treatment with dupilumab and
during follow-up in skin biopsies from AD participants with chronic pruritus
- To evaluate the efficacy of dupilumab in AD participants with chronic pruritus
- To evaluate the safety of dupilumab in adult participants with moderate-to-severe AD
Phase
Phase 4
Funding Agency/Sponsor
Industry
Disease
Other
Enrollment Eligibility
Inclusion criteria :
For Atopic dermatitis patients
- Male or female of ≥18 years of age inclusive, at the time of signing the informed
consent form (ICF).
- Diagnosed with moderate-to-severe chronic AD for at least 1 year before screening.
- Eligible to be treated with dupilumab according to product monograph.
- Pruritus lasting 6 or more weeks before baseline (Day 1).
- Eczema Area and Severity Index (EASI) score ≥12 at baseline.
- Pruritus numerical rating scale (NRS) ≥4 at baseline.
- Investigator global assessment (IGA) score of ≥3 at screening (on the 0 to 4 scale) at
baseline.
- Atopic dermatitis active lesions on the upper limbs or lower limbs suitable for a skin
biopsy without oozing, bleeding, or infection on upper limbs or trunk.
- Patients with acute AD lesions as determined by Investigator's judgment.
- Stable treatment with non-prohibited medication or therapy during the study.
For Healthy participants
- Male or female of ≥18 years of age inclusive, at the time of signing the ICF.
- Certified as generally healthy by a comprehensive clinical assessment
Exclusion criteria:
For atopic dermatitis patients
- Previous treatment with dupilumab stopped within 6 months of baseline due to
inadequate response to dupilumab.
- Skin conditions other than AD that can confound assessments in the opinion of the
investigator.
- Regular use (>2 visits per week) of a tanning booth/parlor within 4 weeks of the
Screening Visit.
- Severe concomitant illness(es) that, in the Investigator's judgment, would adversely
affect the patient's participation in the study.
- Patients with active tuberculosis (TB) or non-TB mycobacterial infection, or a history
of incompletely treated TB unless it is well documented the participant has been
adequately treated and can now start treatment with a biologic agent
- Diagnosed with, suspected of, or at high risk of endoparasitic infection, and/or use
of antiparasitic drug within 2 weeks before the Screening Visit (Visit 1) or during
the Screening Period.
- Active chronic or acute infection requiring treatment with systemic antibiotics,
antivirals,or antifungals within 2 weeks before the Screening Visit (Visit 1) or
during the Screening Period.
- Known or suspected immunodeficiency, including history of invasive opportunistic
infections
- Active malignancy or history of malignancy within 5 years before the Baseline Visit,
except completely treated in situ carcinoma of the cervix and completely treated and
resolved non-metastatic squamous or basal cell carcinoma of the skin.
- Ocular disorder that in the opinion of the Investigator could adversely affect the
individual's risk for study participation. Examples include, but are not limited
to,individuals with a history of active cases of herpes keratitis, Sjogren's syndrome,
keratoconjunctivitis sicca or dry eye syndrome that require daily use of supplemental
lubrication or individuals with ocular conditions that require the use of ocular
corticosteroids or cyclosporine.
- History of systemic hypersensitivity or anaphylaxis to dupilumab or any other biologic
therapy, including any excipient.
- Participant with any other medical or psychological condition including relevant
laboratory or electrocardiogram abnormalities at screening
For healthy participants
- Regular use (>2 visits per week) of a tanning booth/ parlor within 4 weeks of the
Screening Visit
- Treatment with the following concomitant medications and procedures is prohibited
within 4 weeks before the Screening Visit or 5 half-lives (whichever is longer) until
End of Study Visit:
- Topical medication
- Analgesics
- Immunomodulators
- Antidepressants
- Anti-anxiety drugs
- Any Type 2 immune disorders uncontrolled Type 2 diabetes mellitus, Type 1 diabetes
mellitus, neuropathy or any other neurological disease.
- Any concomitant illness(es) or conditions that, in the Investigator's judgment, would
adversely affect the subject's participation in the study or potentially affect any
skin biopsy related read out.
- Positive test for immunoglobulin E (IgE) antibodies.
The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.
Accepts Healthy Volunteers
Call +1 (305) 6892646